Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines

被引:69
作者
Efferth, T
Sauerbrey, A
Halatsch, ME
Ross, DD
Gebhart, E
机构
[1] Univ Jena, Dept Pediat, D-6900 Jena, Germany
[2] Univ Gottingen, Dept Neurosurg, D-3400 Gottingen, Germany
[3] Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA
[4] Univ Maryland, Dept Med, Sch Med, Baltimore, MD 21201 USA
[5] Baltimore Vet Med Ctr, Baltimore, MD USA
[6] Univ Erlangen Nurnberg, Inst Human Genet, D-8520 Erlangen, Germany
关键词
chemotherapy; epidermal growth factor receptor; hierarchical cluster analysis; microarray analysis; multidrug resistance; P53;
D O I
10.1007/s00210-002-0632-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Homoharringtonine (HHT) is an ester of cephalotaxine (CET), both of which derive from the Chinese coniferous tree Cephalotaxus hainanensis. HHT inhibited tumor cell growth at molar ranges comparable to established cytostatic drugs, whereas CET was 3-4 orders of magnitude less active. Inhibition concentration 50% (IC50) values of CET and HHT were significantly correlated to doxorubicin, vincristine, methotrexate, cisplatin, or camptothecin in 55 cell lines of the Developmental Therapeutics Program of the National Cancer Institute (NCI, Bethesda, Md., USA). We tested both drugs for resistance of cell lines which selectively overexpress the multidrug resistance (MDR)-conferring genes P-glycoprotein/MDR1 (CEM/ ADR5000), MDR-related protein 1 MRP1 (HL60/AR), and breast cancer resistance protein BCRP (MDA-MB-231-BCRP). A threefold and ninefold resistance to HHT and CET, respectively, was found in CEM/ADR5000 cells, while the other MDR cell lines did not show cross-resistance compared to their drug-sensitive counterparts. As the tumor suppressor p53 is another important factor of chemoresistance, we also analyzed the possibility that p53 affects the response of tumor cells to CET and HHT. Comparing the p53 mutational status of the 55 NCI cell lines (http://dtp.nci.nih.gov) with the IC50 values showed a significant correlation. Thus, CET and HHT were more active in cell lines without p53 mutation. We correlated the IC50 values of CET and HHT with the cell doubling times of the 55 NCI cell lines as proliferation parameter and observed that rapidly growing cells were more susceptible than slowly growing cell lines. We conducted a search mining the NCI's database for the mRNA expression of 465 genes in 55 cell lines and correlated the data with the IC50 values for CET and HHT. Of these genes 61 (=13%) correlated with the IC50 values for CET and 122 (=26%) with the IC50 values for HHT indicating the multifactorial mode of action of these drugs in cancer cells. We have chosen one example from these genes to test a causative role for drug response. U-87MG.DeltaEGFR cells transfected with an epidermal growth factor receptor (EGFR) gene truncated in its extracellular domain through a deletion of exons 2-7 (DeltaEGFR) were 14-fold more resistant to HHT than control cells transfected with mock expression vector or non-transfected cells. The present investigation presents a starting point to dissect the genes and molecular pathways involved in the tumor cells' response to CET and HHT in greater detail.
引用
收藏
页码:56 / 67
页数:12
相关论文
共 48 条
[31]   DNA repair inhibition and cancer therapy [J].
Martin, NMB .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2001, 63 (1-3) :162-170
[32]  
MIZUTANI Y, 1995, CANCER RES, V55, P590
[33]  
MOSCATELLO DK, 1995, CANCER RES, V55, P5536
[34]  
Nagane M, 1996, CANCER RES, V56, P5079
[35]   Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases [J].
Nagane, M ;
Levitzki, A ;
Gazit, A ;
Cavenee, WK ;
Huang, HJS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (10) :5724-5729
[36]   HOMOHARRINGTONINE THERAPY INDUCES RESPONSES IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN LATE CHRONIC PHASE [J].
OBRIEN, S ;
KANTARJIAN, H ;
KEATING, M ;
BERAN, M ;
KOLLER, C ;
ROBERTSON, LE ;
HESTER, J ;
RIOS, M ;
ANDREEFF, M ;
TALPAZ, M .
BLOOD, 1995, 86 (09) :3322-3326
[37]  
OConnor PM, 1997, CANCER RES, V57, P4285
[38]   Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins [J].
Ohndorf, UM ;
Rould, MA ;
He, Q ;
Pabo, CO ;
Lippard, SJ .
NATURE, 1999, 399 (6737) :708-712
[39]  
RHOADS C, 1948, T ASSOC AM PHYSICIAN, V60, P110
[40]  
ROBOZ J, 1982, BIOMED MASS SPECTROM, V9, P510